DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Information source: Fudan University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Metastatic Breast Cancer; Bone Metastases

Intervention: Zoledronic acid (Biological); Zoledronic acid (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Fudan University

Official(s) and/or principal investigator(s):
Xichun Hu, MD, PhD, Principal Investigator, Affiliation: Fudan University

Summary

The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be randomized into two groups.

Clinical Details

Official title: Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Circulating VEGF levels in breast cancer patients with bone metastases

Secondary outcome:

Time to first skeletal-related event

Time to bone progression disease

Progression-free survival

Overall survival

Detailed description: The administration of Zometa in short intervals has been implied to be more potent in maximizing its antitumor and antiangiogenesis effects, while dosing every four weeks is an appropriate strategy for the prevention and management of bone metastases. This study was designed to explore the relationship between dosing of Zometa and level of circulating VEGF.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Signed informed consent

- Female, 18 years or older

- Histologically confirmed invasive breast cancer

- Bone metastases

- ECOG Performance Status of 0 to 2

- Life expectancy of more than 3 months

- Subject must have adequate organ function:

- Cr ≤ 3 mg/dL (265 µmol/L),

- CrCl (Cockcroft & Gault) ≥ 30 mL/min,

- Ca2+ > 8. 0 mg/dL (2. 0 mmol/L) and ≤ 12 mg/dL (3. 0 mmol/L)

- Negative serum pregnancy test for women with childbearing potential

- Good conditions for infusion and willing to undergo phlebotomy during the whole study

- Have ceased anti-tumor treatment including chemotherapy, endocrinotherapy and

bio-targeted therapy for over 28 days Exclusion Criteria:

- Pregnant or lactating females

- History of other malignancy. However, subjects who have been disease-free for 5

years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.

- Concurrent disease or condition that would make the subject inappropriate for study

participation, or any serious medical disorder that would interfere with the subject's safety

- Active or uncontrolled infection

- Current active dental problems including infection of the teeth or jawbone (maxilla

or mandible); dental or fixture trauma; or a current or prior diagnosis of osteonecrosis of the jaw (ONJ); or exposed bone in the mouth; or slow healing after dental procedures

- Recent (within 6 weeks of Randomization) or planned dental or jaw surgery (e. g.

extraction, implants)

- Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart

failure

- Concomitant with liver, brain or symptomatic lung metastases (symptoms such as

hemoptysis, severe cough and shortness of breath)

- Accepted radiotherapy for solitary bone disease within 30 days before study

- Previous treatment with other bisphosphonates or radionuclides within one month

before study

- Known hypersensitivity to bisphosphonates

- History of treatment with calcitonin, gallium nitrate or mithracin within 14 days

before study.

Locations and Contacts

Fudan University Cancer Hospital, Shanghai, Shanghai 200032, China
Additional Information

Related publications:

Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003 Aug 1;9(8):2893-7.

Starting date: November 2006
Last updated: September 13, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017